Clinical Trial Update: The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion [Phase 1]

View source ↗

Summary

A Phase 1 study investigates whether cholinergic signaling mediates the insulin-secreting effects of GIP and Xenin-25 in individuals with prediabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prediabetes

Drugs mentioned

• Xenin-25
• glucose-dependent insulinotropic peptide (GIP) (glucose-dependent insulinotropic peptide)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Pre-diabetes | Phase 1 | Status: COMPLETED